Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Where Today's News Shapes Tomorrow
